News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
182,165 Results
Type
Article (8318)
Company Profile (132)
Press Release (173715)
Section
Business (57972)
Career Advice (350)
Deals (10449)
Drug Delivery (29)
Drug Development (35575)
Employer Resources (70)
FDA (3171)
Job Trends (4574)
News (104932)
Policy (7384)
Tag
Academia (375)
Alliances (13384)
Alzheimer's disease (357)
Approvals (3157)
Artificial intelligence (40)
Bankruptcy (60)
Best Places to Work (3553)
Biotechnology (90)
Cancer (341)
Career advice (300)
CAR-T (38)
Cell therapy (102)
Clinical research (29014)
Collaboration (120)
Compensation (94)
COVID-19 (788)
C-suite (32)
Data (367)
Diabetes (36)
Diagnostics (705)
Earnings (23884)
Employer resources (62)
Events (35931)
Executive appointments (115)
FDA (3313)
Funding (83)
Gene therapy (40)
GLP-1 (210)
Government (806)
Healthcare (2986)
Infectious disease (806)
Inflammatory bowel disease (44)
Interviews (55)
IPO (6075)
Job creations (1089)
Job search strategy (262)
Layoffs (122)
Legal (969)
Lung cancer (66)
Manufacturing (66)
Medical device (768)
Medtech (769)
Mergers & acquisitions (4458)
Metabolic disorders (118)
Neuroscience (437)
NextGen Class of 2024 (1148)
Non-profit (308)
Northern California (535)
Obesity (60)
Opinion (150)
Patents (30)
People (17802)
Pharmaceutical (40)
Phase I (9147)
Phase II (13425)
Phase III (9543)
Pipeline (100)
Podcasts (33)
Policy (35)
Postmarket research (581)
Preclinical (3421)
Radiopharmaceuticals (115)
Rare diseases (49)
Real estate (1308)
Recruiting (29)
Regulatory (5989)
Research institute (416)
Resumes & cover letters (43)
Southern California (454)
Startups (1068)
United States (4366)
Vaccines (141)
Weight loss (36)
Date
Last 7 days (297)
Last 30 days (1006)
Last 365 days (14107)
2024 (11883)
2023 (15748)
2022 (18015)
2021 (19730)
2020 (16823)
2019 (11282)
2018 (8117)
2017 (9850)
2016 (8162)
2015 (10344)
2014 (7658)
2013 (5577)
2012 (5394)
2011 (5422)
2010 (5273)
Location
Africa (206)
Asia (14584)
Australia (1609)
California (1131)
Canada (334)
China (136)
Colorado (40)
Connecticut (44)
Europe (26837)
Florida (116)
Illinois (46)
Indiana (47)
Japan (29)
Kansas (47)
Maryland (150)
Massachusetts (952)
Minnesota (54)
New Jersey (417)
New York (412)
North Carolina (268)
Northern California (535)
Ohio (43)
Pennsylvania (253)
South America (262)
Southern California (454)
Texas (122)
Washington State (112)
182,165 Results for "tc biopharm".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
TC BioPharm Announces Exercise of Warrants for £3.1 Million Gross Proceeds
TC BioPharm plc announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 1,750,000 of the Company’s American Depositary Shares originally issued in December 2023 with an exercise price of £1.5814 per ADS and a term of five years.
May 6, 2024
·
4 min read
Deals
TC BioPharm Announces Execution of Second Non-Binding Letter of Intent for Acquisition, Targeting Innovative CAR-T Therapies
TC BioPharm PLC announced the execution of a non-binding letter of intent to acquire a privately-held biotechnology company pursuing the development of innovative Chimeric Antigen Receptor T-cell therapies for the treatment of refractory cancers and solid tumors.
May 6, 2024
·
5 min read
TC BioPharm to Present at the Sequire Investor Summit
TC BioPharm today announced its participation at the upcoming Sequire Investor Summit 2024 scheduled for January 23-25, 2024.
January 18, 2024
·
2 min read
TC BioPharm Management to Participate at Upcoming 7th CAR-TCR Summit Europe
TC BioPharm PLC announced that CEO, Bryan Kobel and Process Development Manager, Dr. Lauren Bor will be featured “Expert Speakers” at the 7th 7th CAR-TCR Summit Europe, February 27-29th in London, UK.
February 15, 2024
·
1 min read
Deals
TC BioPharm Announces Pricing of $3.5 Million Public Offering
TC BioPharm today announced the pricing of a public offering of 1,750,000 of its American Depositary Shares.
December 19, 2023
·
4 min read
Deals
TC BioPharm Announces Closing of $3.5 Million Public Offering
TC BioPharm today announced the closing of its previously announced public offering of 1,750,000 of its American Depositary Shares.
December 22, 2023
·
4 min read
TC BioPharm Regains Compliance with Nasdaq Minimum Bid Price Requirement
TC BioPharm PLC a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, announced that on January 2, 2024, the Company received a written notice from The Nasdaq Stock Market.
January 4, 2024
·
2 min read
TC BioPharm Announces Additional Cost Reduction Steps to Improve Financial Standing and Streamline Efficiencies
TC BioPharm today announced that the Company is undertaking a series of initiatives to reduce costs and drive efficiency in order to reduce cash burn and expand its financial runway.
January 3, 2024
·
3 min read
TC BioPharm Announces Successful Completion of Safety Cohort and Positive DSMB Results
TC BioPharm (Holdings) PLC (“TC BioPharm” or the “Company”) (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, announces today that the Company has successfully completed its Safety Cohort and received positive review from the Data Safety Monitoring Board (DSMB).
November 14, 2023
·
3 min read
TC BioPharm Announces Plan to Implement ADS Ratio Change
TC BioPharm PLC a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, announced that it will change its ratio of its American Depositary Shares to ordinary shares from one ADS representing one ordinary share to one ADS representing twenty ordinary shares.
December 13, 2023
·
2 min read
1 of 18,217
Next